{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:21:28Z","timestamp":1793866888939,"version":"4.6.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest Radiol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Retrospective studies in patients with primary brain tumors or other central nervous system pathologies as well as postmortem studies have suggested that gadolinium (Gd) deposition occurs in the dentate nucleus (DN) and globus pallidus (GP) after multiple administrations of primarily linear Gd-based contrast agents (GBCAs). However, this deposition has not been associated with any adverse effects or histopathological alterations. The aim of this preclinical study was to systematically examine differences between linear and macrocyclic GBCAs in their potential to induce changes in brain and skin histology including Gd distribution in high spatial resolution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Fifty male Wistar-Han rats were randomly allocated into control (saline, n = 10 rats) and 4 GBCA groups (linear GBCAs: gadodiamide and gadopentetate dimeglumine, macrocyclic GBCAs: gadobutrol and gadoteridol; n = 10 rats per group). The animals received 20 daily intravenous injections at a dose of 2.5 mmol Gd\/kg body weight. Eight weeks after the last GBCA administration, the animals were killed, and the brain and skin samples were histopathologically assessed (hematoxylin and eosin; cresyl violet [Nissl]) and by immunohistochemistry. The Gd concentration in the skin, bone, brain, and skeletal muscle samples were analyzed using inductively coupled plasma mass spectroscopy (ICP-MS, n = 4). The spatial Gd distribution in the brain and skin samples was analyzed in cryosections using laser ablation coupled with ICP-MS (LA-ICP-MS, n = 3). For the ultra-high resolution of Gd distribution, brain sections of rats injected with gadodiamide or saline (n = 1) were assessed by scanning electron microscopy coupled to energy dispersive x-ray spectroscopy and transmission electron microscopy, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No histological changes were observed in the brain. In contrast, 4 of 10 animals in the gadodiamide group but none of the animals in other groups showed macroscopic and histological nephrogenic systemic fibrosis\u2013like skin lesions. The Gd concentrations observed in the skin\/brain samples (in nanomole Gd per gram of tissue) for each agent were as follows: gadodiamide: 1472 \u00b1 115\/11.1 \u00b1 5.1, gadopentetate dimeglumine: 80.8 \u00b1 6.2\/13.1 \u00b1 7.3, gadobutrol: 1.1 \u00b1 0.5\/0.7 \u00b1 0.4, and gadoteridol: 1.7 \u00b1 0.8\/0.5 \u00b1 0.2. The average detected residual Gd concentration in the brain was approximately 15-fold higher for linear than for macrocyclic GBCAs. The highest amounts of Gd found in brain corresponded to less than 0.0002% of the injected dose per gram of tissue. Using LA-ICP-MS, high Gd concentrations in the deep cerebellar nuclei and in the granular layer of the cerebellar cortex were detected only for linear gadodiamide and gadopentetate dimeglumine but not for gadoteridol or gadobutrol. The energy dispersive x-ray spectroscopy analysis revealed Gd-containing spots in the skin of animals administered gadodiamide and gadopentetate dimeglumine. Transmission electron microscopy revealed several Gd-containing spots in the region of the dentate nuclei in the brain of 1 animal injected with gadodiamide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>After repeated high dosing, nephrogenic systemic fibrosis\u2013like macroscopic and histopathological lesions of the skin were observed only in some of the gadodiamide-treated animals. No histopathological findings were detected in the rodent brain. The administration of linear GBCAs was associated with significantly higher Gd concentrations in the brain and skin compared with macrocyclic GBCA administration. The results of LA-ICP-MS demonstrated local accumulation of Gd within the deep cerebellar nuclei and the granular layer only after the administration of linear agents. In summary, the detected low Gd concentrations in the skin and brain were well correlated with the higher kinetic stability of macrocyclic GBCA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rli.0000000000000344","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T20:08:09Z","timestamp":1490126889000},"page":"324-333","source":"Crossref","is-referenced-by-count":174,"title":["Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents"],"prefix":"10.1097","volume":"52","author":[{"given":"Jessica","family":"Lohrke","sequence":"first","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Frisk","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frenzel","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sch\u00f6ckel","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rosenbruch","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Jost","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Constanze","family":"Lenhard","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Sieber","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Nischwitz","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"K\u00fcppers","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Pietsch","sequence":"additional","affiliation":[{"name":"From the *MR and CT Contrast Media Research, \u2020Research Pathology Berlin, and \u2021Medical and Clinical Affairs Radiology, Bayer AG, Berlin; \u00a7Special Histopathology, Bayer AG, Elberfeld; \u2225Institute of Vegetative Physiology, Charit\u00e9; \u00b6Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20231021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI: developments, current challenges and future perspectives","volume":"33","year":"2016","journal-title":"Adv Ther"},{"key":"bib2-20231021","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","article-title":"Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C","volume":"43","year":"2008","journal-title":"Invest Radiol"},{"key":"bib3-20231021","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","article-title":"Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions","volume":"18","year":"2008","journal-title":"Eur Radiol"},{"key":"bib4-20231021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","article-title":"Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?","volume":"80","year":"2007","journal-title":"Br J Radiol"},{"key":"bib5-20231021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.rli.0000253505.88945.d5","article-title":"Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan)","volume":"42","year":"2007","journal-title":"Invest Radiol"},{"key":"bib6-20231021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1259\/bjr\/17326033","article-title":"Stability of linear and macrocyclic gadolinium based contrast agents","volume":"80","year":"2007","journal-title":"Br J Radiol"},{"key":"bib7-20231021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00330-012-2597-9","article-title":"Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines","volume":"23","year":"2013","journal-title":"Eur Radiol"},{"key":"bib8-20231021","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","year":"2014","journal-title":"Radiology"},{"key":"bib9-20231021","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","year":"2014","journal-title":"Invest Radiol"},{"key":"bib10-20231021","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib11-20231021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1148\/radiol.14140364","article-title":"High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib12-20231021","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3174\/ajnr.A4378","article-title":"Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration","volume":"36","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib13-20231021","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1148\/radiol.2015150337","article-title":"Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib14-20231021","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2214\/AJR.15.15327","article-title":"Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol","volume":"206","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"bib15-20231021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/RLI.0000000000000206","article-title":"Increased signal intensity in the dentate nucleus on unenhanced T1-Weighted images after gadobenate dimeglumine administration","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib16-20231021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1148\/radiol.2015150872","article-title":"High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents","volume":"276","year":"2015","journal-title":"Radiology"},{"key":"bib17-20231021","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/RLI.0000000000000227","article-title":"High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib18-20231021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2015142690","article-title":"Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy","volume":"276","year":"2015","journal-title":"Radiology"},{"key":"bib19-20231021","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2214\/AJR.15.15842","article-title":"Gadolinium in humans: a family of disorders","volume":"207","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"bib20-20231021","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","article-title":"Self-reported gadolinium toxicity: a survey of patients with chronic symptoms","volume":"34","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"bib21-20231021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLI.0000000000000242","article-title":"Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents: comparison of linear and macrocyclic agents","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib22-20231021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/RLI.0000000000000181","article-title":"T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib23-20231021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/RLI.0000000000000241","article-title":"Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib24-20231021","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/0192623312474865","article-title":"STP position paper: recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies","volume":"41","year":"2013","journal-title":"Toxicol Pathol"},{"key":"bib25-20231021","first-page":"535","article-title":"Current status review: cerebral amyloid","volume":"73","year":"1992","journal-title":"Int J Exp Pathol"},{"issue":"suppl 4","key":"bib26-20231021","first-page":"87S","article-title":"Proliferative and nonproliferative lesions of the rat and mouse central and peripheral nervous systems","volume":"40","year":"2012","journal-title":"Toxicol Pathol"},{"key":"bib27-20231021","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1111\/febs.13412","article-title":"The dynamic blood-brain barrier","volume":"282","year":"2015","journal-title":"FEBS J"},{"key":"bib28-20231021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/01926230490268756","article-title":"Best practices guideline: toxicologic histopathology","volume":"32","year":"2004","journal-title":"Toxicol Pathol"},{"key":"bib29-20231021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0192623312438737","article-title":"Regulatory forum opinion piece: blind reading of histopathology slides in general toxicology studies","volume":"40","year":"2012","journal-title":"Toxicol Pathol"},{"key":"bib30-20231021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10520296009114754","article-title":"Embedding in epoxy resins for ultrathin sectioning in electron microscopy","volume":"35","year":"1960","journal-title":"Stain Technol"},{"key":"bib31-20231021","doi-asserted-by":"crossref","first-page":"e58702","DOI":"10.1371\/journal.pone.0058702","article-title":"Novel bioimaging techniques of metals by laser ablation inductively coupled plasma mass spectrometry for diagnosis of fibrotic and cirrhotic liver disorders","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"bib32-20231021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2202-15-98","article-title":"Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry","volume":"15","year":"2014","journal-title":"BMC Neurosci"},{"key":"bib33-20231021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijms.2011.03.010","article-title":"IMAGENA: Image Generation and Analysis\u2014An interactive software tool handling LA-ICP-MS data","volume":"307","year":"2011","journal-title":"Int J Mass Spectrom"},{"key":"bib34-20231021","article-title":"Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study","year":"2016","journal-title":"Radiology"},{"key":"bib35-20231021","doi-asserted-by":"crossref","first-page":"20160509","DOI":"10.1259\/bjr.20160509","article-title":"Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model","volume":"89","year":"2016","journal-title":"Br J Radiol"},{"key":"bib36-20231021","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/RLI.0000000000000295","article-title":"Impact of impaired renal function on gadolinium retention after administration of gadolinium-based contrast agents in a mouse model","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib37-20231021","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00330-008-1259-4","article-title":"Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents","volume":"19","year":"2009","journal-title":"Eur Radiol"},{"key":"bib38-20231021","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","article-title":"Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"issue":"suppl 1","key":"bib39-20231021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1289\/ehp.96104s185","article-title":"Exposure, metabolism, and toxicity of rare earths and related compounds","volume":"104","year":"1996","journal-title":"Environ Health Perspect"},{"key":"bib40-20231021","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cmmi.1500","article-title":"Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd(3)(+) to the glycosaminoglycan heparin","volume":"8","year":"2013","journal-title":"Contrast Media Mol Imaging"},{"key":"bib41-20231021","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1039\/b510982p","article-title":"Strategies for increasing the sensitivity of gadolinium based MRI contrast agents","volume":"35","year":"2006","journal-title":"Chem Soc Rev"},{"key":"bib42-20231021","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0730-725X(98)00203-3","article-title":"Utilization of the nephrectomized mouse for determining threshold effects of MRI contrast agents","volume":"17","year":"1999","journal-title":"Magn Reson Imaging"},{"key":"bib43-20231021","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004424-199506000-00008","article-title":"Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats","volume":"30","year":"1995","journal-title":"Invest Radiol"},{"key":"bib44-20231021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","year":"2011","journal-title":"Fluids Barriers CNS"},{"key":"bib45-20231021","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3174\/ajnr.A0725","article-title":"Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium?","volume":"28","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib46-20231021","article-title":"Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue","year":"2016","journal-title":"Eur Radiol"},{"key":"bib47-20231021","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1172\/JCI67677","article-title":"Brain-wide pathway for waste clearance captured by contrast-enhanced MRI","volume":"123","year":"2013","journal-title":"J Clin Invest"},{"key":"bib48-20231021","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The glymphatic system: a beginner's guide","volume":"40","year":"2015","journal-title":"Neurochem Res"},{"key":"bib49-20231021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11307-012-0579-6","article-title":"Transferrin-coated gadolinium nanoparticles as MRI contrast agent","volume":"15","year":"2013","journal-title":"Mol Imaging Biol"},{"key":"bib50-20231021","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1073\/pnas.1423021112","article-title":"Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging","volume":"112","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib51-20231021","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/RLI.0000000000000154","article-title":"Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib52-20231021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/RLI.0000000000000273","article-title":"Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib53-20231021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/RLI.0000000000000182","article-title":"Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents","volume":"50","year":"2015","journal-title":"Invest Radiol"}],"container-title":["Investigative Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004424-201706000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:22:34Z","timestamp":1697865754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004424-201706000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rli.0000000000000344","relation":{},"ISSN":["1536-0210","0020-9996"],"issn-type":[{"value":"1536-0210","type":"electronic"},{"value":"0020-9996","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}